Jarrett Rosenberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jarrett Rosenberg has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Greg Zaharchuk
Department of Radiology Stanford University Palo Alto California USA
3 shared publications - Michael E. Moseley
From the Department of Radiology (Y.L., B.J., H.v.V., H.F., Z.Z., S. Luo, M.E.M., J.J.H., G.Z.), Stanford University, Stanford, California
3 shared publications - Audrey Peiwen Fan
Department of Biomedical Engineering, University of California, Davis, Davis, CA, United States
2 shared publications - Michael Zeineh
Department of Radiology, Stanford University, USA
2 shared publications - Nancy Fischbein
From the Department of Radiology (I.T.V., N.F., N.P.), Pathology (M.R.), Stanford University School of Medicine, Stanford, CA; Department of Radiology (V.S.), University of California, Los Angeles David Geffen School of Medicine, CA and Department of Radiology (B.D.), Kaiser Permanente, Sacramento, CA
2 shared publications - Sanjiv Sam Gambhir
Department of Radiology, Stanford University School of Medicine, Stanford, California 94304, United States
2 shared publications
Latest Publications
- 13 April 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 111 (2) , 689-702
Characterizing ferrous versus ferric iron in Alzheimer's disease using X-ray fluorescence imaging and XANES spectroscopy
Background: The accumulation of iron, such as ferrous Fe 2+ , in the Alzheimer's disease (AD) brain may contribute to neurodegeneration by driving oxidative stress. While elevated iron in AD has been shown, the oxidation state of iron and its regional distribution in AD, particularly in the hippocampus, is unclear. Objective: To characterize the oxidation state and spatial distribution of iron in the hippocampus of AD and control brains, and to assess the effect of tissue thawing on ferrous iron measurements. Methods: We utilized X-ray fluorescence imaging and X-ray absorption near edge structure spectroscopy to localize and analyze iron deposition in fresh-frozen human hippocampal specimens stratified by AD disease stage. To assess the effect of thawing on iron oxidation, we used a cryo-chamber to keep three specimens frozen while their respective deposits were being scanned. These specimens were then allowed to thaw and their same deposits were rescanned for comparison. Results: Compared to control brains, AD specimens exhibited elevated levels of ferrous iron (Fe 2 + ) in the cornu ammonis 1 (CA1)-subiculum subfields—regions known to degenerate early in AD. We also measured a decrease in Fe 2+ levels in AD and control specimens scanned after being thawed. Conclusions: Our findings support the association between elevated Fe 2+ and AD, consistent with existing hypotheses linking redox-active iron to oxidative stress and neuroinflammation. The observed reduction in Fe 2+ levels following thawing suggests that studies using thawed brain samples may underestimate Fe 2+ levels.
- 13 April 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 111 (2) , 689-702
Characterizing ferrous versus ferric iron in Alzheimer's disease using X-ray fluorescence imaging and XANES spectroscopy
Background: The accumulation of iron, such as ferrous Fe 2+ , in the Alzheimer's disease (AD) brain may contribute to neurodegeneration by driving oxidative stress. While elevated iron in AD has been shown, the oxidation state of iron and its regional distribution in AD, particularly in the hippocampus, is unclear. Objective: To characterize the oxidation state and spatial distribution of iron in the hippocampus of AD and control brains, and to assess the effect of tissue thawing on ferrous iron measurements. Methods: We utilized X-ray fluorescence imaging and X-ray absorption near edge structure spectroscopy to localize and analyze iron deposition in fresh-frozen human hippocampal specimens stratified by AD disease stage. To assess the effect of thawing on iron oxidation, we used a cryo-chamber to keep three specimens frozen while their respective deposits were being scanned. These specimens were then allowed to thaw and their same deposits were rescanned for comparison. Results: Compared to control brains, AD specimens exhibited elevated levels of ferrous iron (Fe 2 + ) in the cornu ammonis 1 (CA1)-subiculum subfields—regions known to degenerate early in AD. We also measured a decrease in Fe 2+ levels in AD and control specimens scanned after being thawed. Conclusions: Our findings support the association between elevated Fe 2+ and AD, consistent with existing hypotheses linking redox-active iron to oxidative stress and neuroinflammation. The observed reduction in Fe 2+ levels following thawing suggests that studies using thawed brain samples may underestimate Fe 2+ levels.
- 6 August 2025
- Published by Wiley in NMR in Biomedicine
- Vol. 38 (9) , e70112
Improved Strength Prediction Combining MRI Biomarkers of Muscle Quantity and Quality
Muscle strength declines with aging at a faster rate compared with muscle mass, suggesting that not only muscle quantity but also muscle quality and architecture are age‐dependent. This study tested the hypothesis that quantitative MRI (qMRI)‐derived biomarkers of muscle quality (fractional anisotropy [FA], radial diffusivity [RD], axial diffusivity [AD], fat fraction [FF], and T2 relaxation time) and architecture (fascicle length) could improve the prediction of skeletal muscle strength over muscle mass alone. We recruited 24 adults (12 female, age range 30–79 years). Muscle mass was estimated as the volume and cross‐sectional area (CSA) of the quadriceps. FA, RD, and AD parameters, together with fascicle length for the rectus femoris (RF) and vastus lateralis (VL), were derived from diffusion tensor imaging (DTI), and muscle‐T2 was calculated from a multi‐echo spin echo sequence. FF was determined using the Dixon approach. CSA values were combined with FF to calculate the lean CSA. Isometric, eccentric, and concentric knee extension torques were measured for the left and right leg using an isokinetic dynamometer. The univariable assessment of torque was performed using a linear regression. The statistical significance of adding qMRI parameters to the torque prediction models was tested using a mixed‐effect regression. The best univariable predictor of isometric, eccentric, and concentric torque was lean CSA. Adding FA, RF fascicle length, and VL fascicle length to the model improved the prediction of concentric torque compared with CSA alone. The addition of FA, T2, RD, RF fascicle length, and VL fascicle length improved the prediction of eccentric torque over CSA alone. The addition of FF was not significant within the model. Our results confirmed the hypothesis that the inclusion of qMRI parameters of muscle composition and architecture leads to higher R2 coefficients for the prediction of muscle strength compared with models solely based on muscle quantity. These observations support the utility of qMRI for future research on sarcopenia prediction and management.
- 6 August 2025
- Published by Wiley in NMR in Biomedicine
- Vol. 38 (9) , e70112
Improved Strength Prediction Combining MRI Biomarkers of Muscle Quantity and Quality
Muscle strength declines with aging at a faster rate compared with muscle mass, suggesting that not only muscle quantity but also muscle quality and architecture are age‐dependent. This study tested the hypothesis that quantitative MRI (qMRI)‐derived biomarkers of muscle quality (fractional anisotropy [FA], radial diffusivity [RD], axial diffusivity [AD], fat fraction [FF], and T2 relaxation time) and architecture (fascicle length) could improve the prediction of skeletal muscle strength over muscle mass alone. We recruited 24 adults (12 female, age range 30–79 years). Muscle mass was estimated as the volume and cross‐sectional area (CSA) of the quadriceps. FA, RD, and AD parameters, together with fascicle length for the rectus femoris (RF) and vastus lateralis (VL), were derived from diffusion tensor imaging (DTI), and muscle‐T2 was calculated from a multi‐echo spin echo sequence. FF was determined using the Dixon approach. CSA values were combined with FF to calculate the lean CSA. Isometric, eccentric, and concentric knee extension torques were measured for the left and right leg using an isokinetic dynamometer. The univariable assessment of torque was performed using a linear regression. The statistical significance of adding qMRI parameters to the torque prediction models was tested using a mixed‐effect regression. The best univariable predictor of isometric, eccentric, and concentric torque was lean CSA. Adding FA, RF fascicle length, and VL fascicle length to the model improved the prediction of concentric torque compared with CSA alone. The addition of FA, T2, RD, RF fascicle length, and VL fascicle length improved the prediction of eccentric torque over CSA alone. The addition of FF was not significant within the model. Our results confirmed the hypothesis that the inclusion of qMRI parameters of muscle composition and architecture leads to higher R2 coefficients for the prediction of muscle strength compared with models solely based on muscle quantity. These observations support the utility of qMRI for future research on sarcopenia prediction and management.
- 6 May 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Radiation and Plasma Medical Sciences
- Vol. 8 (6) , 677-689
Context-Aware Transformer GAN for Direct Generation of Attenuation and Scatter Corrected PET Data
We present a context-aware generative deep learning framework to produce photon attenuation and scatter corrected (ASC) PET images directly from non-attenuation and non-scatter corrected (NASC) images. We trained conditional generative adversarial networks (cGAN) on either single-modality (NASC) or multi-modality (NASC+MRI) input data to map NASC images to pixel-wise continuously valued ASC PET images. We designed and evaluated four cGAN models including Pix2Pix, attention-guided cGAN (AG-Pix2Pix), vision transformer cGAN (ViT-GAN), and shifted window transformer cGAN (Swin-GAN). Retrospective 18F-fluorodeoxyglucose (18F-FDG) full-body PET images from 33 subjects were collected and analyzed. Notably, as a particular strength of this work, each patient in the study underwent both a PET/CT scan and a multisequence PET/MRI scan on the same day giving us a gold standard from the former as we investigate ASC for the latter. Quantitative analysis, evaluating image quality using peak signal-to-noise ratio (PSNR), multi-scale structural similarity index (MS-SSIM), normalized mean squared error (NRMSE), and mean absolute error (MAE) metrics, showed no significant impact of input type on PSNR (p=0.95), MS-SSIM (p=0.083), NRMSE (p=0.72), or MAE (p=0.70). For multi-modal input data, Swin-GAN outperformed Pix2Pix (p=0.023) and AG-Pix2Pix (p<0.001), but not ViT-GAN (p=0.154) in PSNR. Swin-GAN achieved significantly higher MS-SSIM than ViT-GAN (p=0.007) and AG-Pix2Pix (p=0.002). Multi-modal Swin-GAN demonstrated reduced NRMSE and MAE compared to ViT-GAN (p=0.023 and 0.031, respectively) and AG-Pix2Pix (both p<0.001), with marginal improvement over Pix2Pix (p<0.064). The cGAN models, in particular Swin-GAN, consistently generated reliable and accurate ASC PET images, whether using multi-modal or single-modal input data. The findings indicate this methodology can be used to generate ASC data from standalone PET scanners or integrated PET/MRI systems, without relying on transmission scan-based attenuation maps.
- 6 May 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Radiation and Plasma Medical Sciences
- Vol. 8 (6) , 677-689
Context-Aware Transformer GAN for Direct Generation of Attenuation and Scatter Corrected PET Data
We present a context-aware generative deep learning framework to produce photon attenuation and scatter corrected (ASC) PET images directly from non-attenuation and non-scatter corrected (NASC) images. We trained conditional generative adversarial networks (cGAN) on either single-modality (NASC) or multi-modality (NASC+MRI) input data to map NASC images to pixel-wise continuously valued ASC PET images. We designed and evaluated four cGAN models including Pix2Pix, attention-guided cGAN (AG-Pix2Pix), vision transformer cGAN (ViT-GAN), and shifted window transformer cGAN (Swin-GAN). Retrospective 18F-fluorodeoxyglucose (18F-FDG) full-body PET images from 33 subjects were collected and analyzed. Notably, as a particular strength of this work, each patient in the study underwent both a PET/CT scan and a multisequence PET/MRI scan on the same day giving us a gold standard from the former as we investigate ASC for the latter. Quantitative analysis, evaluating image quality using peak signal-to-noise ratio (PSNR), multi-scale structural similarity index (MS-SSIM), normalized mean squared error (NRMSE), and mean absolute error (MAE) metrics, showed no significant impact of input type on PSNR (p=0.95), MS-SSIM (p=0.083), NRMSE (p=0.72), or MAE (p=0.70). For multi-modal input data, Swin-GAN outperformed Pix2Pix (p=0.023) and AG-Pix2Pix (p<0.001), but not ViT-GAN (p=0.154) in PSNR. Swin-GAN achieved significantly higher MS-SSIM than ViT-GAN (p=0.007) and AG-Pix2Pix (p=0.002). Multi-modal Swin-GAN demonstrated reduced NRMSE and MAE compared to ViT-GAN (p=0.023 and 0.031, respectively) and AG-Pix2Pix (both p<0.001), with marginal improvement over Pix2Pix (p<0.064). The cGAN models, in particular Swin-GAN, consistently generated reliable and accurate ASC PET images, whether using multi-modal or single-modal input data. The findings indicate this methodology can be used to generate ASC data from standalone PET scanners or integrated PET/MRI systems, without relying on transmission scan-based attenuation maps.
- 22 February 2022
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 303 (3) , 620-631
18F-FSPG PET/CT Imaging of System xC– Transporter Activity in Patients with Primary and Metastatic Brain Tumors
PET/CT with (4S)-4-(3-[18F]fluoropropyl)-l-glutamate had high sensitivity for detecting primary brain cancers and brain metastases and could help predict primary brain tumor outcomes using informat... Background The PET tracer (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (18F-FSPG) targets the system xC– cotransporter, which is overexpressed in various tumors. Purpose To assess the role of 18F-FSPG ...
- 22 February 2022
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 303 (3) , 620-631
18F-FSPG PET/CT Imaging of System xC– Transporter Activity in Patients with Primary and Metastatic Brain Tumors
PET/CT with (4S)-4-(3-[18F]fluoropropyl)-l-glutamate had high sensitivity for detecting primary brain cancers and brain metastases and could help predict primary brain tumor outcomes using informat... Background The PET tracer (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (18F-FSPG) targets the system xC– cotransporter, which is overexpressed in various tumors. Purpose To assess the role of 18F-FSPG ...
- 1 November 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 297 (2) , 438-446
Brain Iron Assessment after Ferumoxytol-enhanced MRI in Children and Young Adults with Arteriovenous Malformations: A Case-Control Study
No signal differences were found in the brains of children and young adults with arteriovenous malformations following single and multiple ferumoxytol administrations to suggest brain iron retention. Background Iron oxide nanoparticles are an alternative contrast agent for MRI. Gadolinium deposition has raised safety concerns, but it is unknown whether ferumoxytol administration also deposits i...
- 1 November 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 297 (2) , 438-446
Brain Iron Assessment after Ferumoxytol-enhanced MRI in Children and Young Adults with Arteriovenous Malformations: A Case-Control Study
No signal differences were found in the brains of children and young adults with arteriovenous malformations following single and multiple ferumoxytol administrations to suggest brain iron retention. Background Iron oxide nanoparticles are an alternative contrast agent for MRI. Gadolinium deposition has raised safety concerns, but it is unknown whether ferumoxytol administration also deposits i...
- Open Access
- 1 October 2020
- Published by Elsevier in NeuroImage
- Vol. 220, 117136
Quantification of brain oxygen extraction and metabolism with [15O]-gas PET: A technical review in the era of PET/MRI
- 1 October 2020
- Published by Elsevier in NeuroImage
- Vol. 220, 117136
Open AccessQuantification of brain oxygen extraction and metabolism with [15O]-gas PET: A technical review in the era of PET/MRI
- 5 May 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 296 (1) , 143-151
Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI
Our data showed significant agreement between response assessments at whole-body diffusion-weighted MRI and fluorine 18 fluorodeoxyglucose PET/MRI after induction chemotherapy; the agreement after ... Background Whole-body diffusion-weighted (DW) MRI can help detect cancer with high sensitivity. However, the assessment of therapy response often requires information about tumor metabolism, which ...
- 5 May 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 296 (1) , 143-151
Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI
Our data showed significant agreement between response assessments at whole-body diffusion-weighted MRI and fluorine 18 fluorodeoxyglucose PET/MRI after induction chemotherapy; the agreement after ... Background Whole-body diffusion-weighted (DW) MRI can help detect cancer with high sensitivity. However, the assessment of therapy response often requires information about tumor metabolism, which ...
- Open Access
- 1 January 2020
- Published by Ivyspring International Publisher in Nanotheranostics
- Vol. 4 (4) , 210-223
Histologic evaluation of activation of acute inflammatory response in a mouse model following ultrasound-mediated blood-brain barrier using different acoustic pressures and microbubble doses
Rationale: Localized blood-brain barrier (BBB) opening can be achieved with minimal to no tissue damage by applying pulsed focused ultrasound alongside a low microbubble (MB) dose. However, relatively little is known regarding how varying treatment parameters affect the degree of neuroinflammation following BBB opening. The goal of this study was to evaluate the activation of an inflammatory response following BBB opening as a function of applied acoustic pressure using two different microbubble doses.
- 1 January 2020
- Published by Ivyspring International Publisher in Nanotheranostics
- Vol. 4 (4) , 210-223
Open AccessHistologic evaluation of activation of acute inflammatory response in a mouse model following ultrasound-mediated blood-brain barrier using different acoustic pressures and microbubble doses
Rationale: Localized blood-brain barrier (BBB) opening can be achieved with minimal to no tissue damage by applying pulsed focused ultrasound alongside a low microbubble (MB) dose. However, relatively little is known regarding how varying treatment parameters affect the degree of neuroinflammation following BBB opening. The goal of this study was to evaluate the activation of an inflammatory response following BBB opening as a function of applied acoustic pressure using two different microbubble doses.
- 1 December 2018
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 29 (12) , 1672-1677
Quantification of Activity Lost to Delivery-System Residual and Decay in Yttrium-90 Radioembolization
- 1 December 2018
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 29 (12) , 1672-1677
Quantification of Activity Lost to Delivery-System Residual and Decay in Yttrium-90 Radioembolization
- Open Access
- 6 November 2017
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 19 (suppl_6) , vi61-vi62
DDIS-15. SYNERGISTIC INHIBITION OF GLIOMA CELL PROLIFERATION BY WITHAFERIN A AND TUMOR TREATING FIELDS
Glioblastoma (GBM) is the most aggressive and lethal form of primary brain cancer. Standard therapies are non-specific and often of limited effectiveness; thus, efforts are underway to uncover novel, unorthodox therapies against GBM. In previous studies, we investigated Withaferin A, a steroidal lactone from Ayurvedic medicine that inhibits proliferation in cancers including GBM. Another novel approach, tumor treating fields (TTFields), is thought to disrupt mitotic spindle formation and stymie proliferation of actively dividing cells. We hypothesized that combining TTFields with Withaferin A would synergistically inhibit proliferation in glioblastoma. Human glioblastoma cells (GBM2, GBM39, U87-MG) and human breast adenocarcinoma cells (MDA-MB-231) were isolated from primary tumors. The glioma cell lines were genetically engineered to express firefly luciferase. Proliferative potential was assessed either by bioluminescence imaging or cell counting via hemocytometer. TTFields (4 V/cm) significantly inhibited growth of the four cancer cell lines tested (n=3 experiments per time point, 4 measurements per sample, p<0.02 at least; 2-way ANOVA, control vs. treatment). The combination of Withaferin A (10–100 nM) with TTFields significantly inhibited the growth of the glioma cells to a degree beyond that of Withaferin A or TTFields alone. The interaction of the Withaferin A and TTFields on glioma cells was found to be synergistic in nature (p<0.01, n=3 experiments). These findings were validated by both bioluminescence and hemocytometric measurements. The combination of Withaferin A with TTFields represents a novel approach to treat GBM in a manner that is likely better than either treatment alone and that is synergistic.
- 6 November 2017
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 19 (suppl_6) , vi61-vi62
Open AccessDDIS-15. SYNERGISTIC INHIBITION OF GLIOMA CELL PROLIFERATION BY WITHAFERIN A AND TUMOR TREATING FIELDS
Glioblastoma (GBM) is the most aggressive and lethal form of primary brain cancer. Standard therapies are non-specific and often of limited effectiveness; thus, efforts are underway to uncover novel, unorthodox therapies against GBM. In previous studies, we investigated Withaferin A, a steroidal lactone from Ayurvedic medicine that inhibits proliferation in cancers including GBM. Another novel approach, tumor treating fields (TTFields), is thought to disrupt mitotic spindle formation and stymie proliferation of actively dividing cells. We hypothesized that combining TTFields with Withaferin A would synergistically inhibit proliferation in glioblastoma. Human glioblastoma cells (GBM2, GBM39, U87-MG) and human breast adenocarcinoma cells (MDA-MB-231) were isolated from primary tumors. The glioma cell lines were genetically engineered to express firefly luciferase. Proliferative potential was assessed either by bioluminescence imaging or cell counting via hemocytometer. TTFields (4 V/cm) significantly inhibited growth of the four cancer cell lines tested (n=3 experiments per time point, 4 measurements per sample, p<0.02 at least; 2-way ANOVA, control vs. treatment). The combination of Withaferin A (10–100 nM) with TTFields significantly inhibited the growth of the glioma cells to a degree beyond that of Withaferin A or TTFields alone. The interaction of the Withaferin A and TTFields on glioma cells was found to be synergistic in nature (p<0.01, n=3 experiments). These findings were validated by both bioluminescence and hemocytometric measurements. The combination of Withaferin A with TTFields represents a novel approach to treat GBM in a manner that is likely better than either treatment alone and that is synergistic.